Nasal whooping cough vaccine gets a boost: higher dose tested in adults
NCT ID NCT02453048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a higher dose of a new nasal vaccine (BPZE1) for whooping cough in 54 healthy adults aged 18-32. The goal was to see if the higher dose is safe and helps the vaccine take hold in the nose to trigger protection. Researchers monitored side effects and checked if the vaccine colonized the nose over 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karolinska University Hospital
Huddinge, Stockholm County, 141 86, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older kids and adults from three deadly infections?
- Can a Five-Part vaccine bolster protection against three serious infections?
- Will a single DTP vaccine dose protect for a decade? study tracks antibodies
- Scientists create controlled whooping cough infection to speed up vaccine research
- New vaccine for moms could shield babies from whooping cough
- New Low-Dose tdap vaccine trial aims to boost protection with fewer side effects